Shotwise

Shotwise has proven paying customers and recurring revenue, which is a useful baseline: $1,163 in the last 30 days and $1,299 MRR show an active commercial product in the GLP-1 weight-loss management niche. The product category is clear — helping users manage GLP-1 treatments and track progress — so the market need is well defined even if small today.

Two signals stand out for different reasons. The reported margin of 85% suggests the economics are healthy at current scale, making it possible to be cash-generative quickly. At the same time, growth is flat (0%), and absolute revenue is modest; that combination means the upside depends on execution (customer acquisition or product expansion) rather than on operational fixes alone. The fact the company is listed for sale is another operational signal investors or buyers will want to investigate closely (motivation, retention, support burden).

◆ Best suited for

A judgment from project data — not a user review.